ROCKET PHARMACEUTICALS, INC.
RCKT · XNASCIK 1281895fmd_17ETGGX1K5GJSHV93XZGH05N7KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property operating expenses | – | – | – | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 6 | 15 | 53 | 58 | 105 | 125 | 166 | 186 | 171 | 142 |
| Total operating expenses | 8 | 20 | 71 | 76 | 134 | 167 | 224 | 260 | 273 | 232 |
| Operating income | (8) | (20) | (71) | (76) | (134) | (167) | (224) | (260) | (273) | (232) |
| Interest expense | 0 | 0 | 6 | 6 | 7 | 3 | 2 | 2 | 2 | 2 |
| Interest and investment income | 0 | 0 | 2 | 3 | 2 | 3 | 4 | 5 | 8 | 3 |
| Other non-operating income (expense) | – | – | – | – | (5) | (2) | 2 | – | – | – |
| Income before taxes | – | – | – | – | – | – | – | – | (259) | (223) |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (259) | (223) |
| Net income | (8) | (20) | (75) | (77) | (140) | (169) | (222) | (246) | (259) | (223) |
| Net income to common shareholders | (8) | (20) | (75) | (77) | (140) | (169) | (222) | (246) | (259) | (223) |